BioNTech to Establish Regional Headquarters for Southeast Asia and First mRNA Manufacturing Plant in Singapore


  • BioNTech to establish first regional hub in Asia-Pacific region in Singapore
  • A planned state-of-the-art manufacturing site will support the global supply of vaccines and mRNA-based therapeutics and provide a rapid response capacity to Southeast Asia against possible future pandemic threats.
  • Expansion plan supported by the Singapore Economic Development Board (EDB)

MAINZ, GERMANY, May 10, 2021BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced its intention to expand its global presence in Asia with the establishment of its regional headquarters for Southeast Asia in Singapore. In addition to choosing Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing plant in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capability of BioNTech’s growing mRNA-based product candidate pipeline, as well as rapid response production capability for Southeast Asia to address potential threats. pandemic.

In line with BioNTech’s mission to develop next-generation immunotherapies to improve the health of individuals around the world, the new mRNA manufacturing facility will leverage state-of-the-art manufacturing and digital infrastructure. It will be equipped to produce a range of new mRNA and therapeutic vaccines for infectious diseases and cancer. The envisioned site will provide highly automated, end-to-end mRNA production capabilities for drug substance, drug product, and filling and finishing, with an estimated annual capacity of several hundred million doses of vaccine-based vaccines. ‘MRNA depending on the specific vaccine. .

BioNTech plans to open its office in Singapore and begin construction of the manufacturing facility in 2021, subject to planning approval. The company predicts that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.

“Having multiple nodes in our production network is an important strategic step in building our global footprint and capabilities. With this planned mRNA production facility, we will increase the overall capacity of our network and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world, ”said Ugur Sahin, MD, CEO and co-founder of BioNTech. “Singapore offers an excellent business climate, a growing biotech industry and a rich talent base. We would like to thank the Singapore Economic Development Board which has been very supportive throughout our planning process and look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region. .

“We warmly welcome BioNTech’s plan to establish its mRNA manufacturing facility and regional headquarters in Singapore. This investment will enable Singapore to build capacity in an important new therapeutic modality as part of our biopharmaceutical industry’s growth strategy, ”said Dr Beh Swan Gin, President, EDB. “In particular, BioNTech’s mRNA manufacturing facility will significantly contribute to the region’s ability to cope with future pandemic threats.”

Following the establishment of its US headquarters in Cambridge, MA in 2020, the establishment of BioNTech’s headquarters in South East Asia represents a key step in the company’s international expansion.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering new therapies against cancer and other serious diseases. The Company leverages a wide range of computer discovery and therapeutic drug platforms for the rapid development of new biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and commercially available mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immunomodulators, targeted anticancer antibodies. and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases, alongside its diverse oncology pipeline. BioNTech has established a wide range of relationships with several global pharmaceutical collaborators including Genmab, Sanofi, Bayer Animal Health, Genentech, Roche Group Member, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech forward-looking statements
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements regarding: BioNTech’s plans for expansion of its manufacturing capacity and capabilities, facilities and geographic presence; Product sales and expected revenues from BioNTech; consumption and expected costs, benefits and synergies of BioNTech’s expansion in Singapore; and BioNTech’s ability to effectively expand its production capabilities and manufacture its products, including the COVID-19 vaccine from BioNTech and Pfizer, and product candidates from BioNTech. All forward-looking statements contained in this press release are based on BioNTech’s current expectations and beliefs regarding future events. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements as they involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BioNTech and what could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

You should review the risks and uncertainties described under “Risk Factors” in BioNTech’s Annual Report on Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC website at www.sec.gov. All information contained in this press release is as of the date of the press release, and BioNTech assumes no obligation to update such information except as required by law.

BioNTech contacts

Media relations
Jasmina alatovic
+49 (0) 6131 9084 1513
[email protected]

Investor Relations
Sylke Maas, Ph.D.
+49 (0) 6131 9084 1074
[email protected]

Main logo



Source link

More Stories
China worries about US withdrawal from Afghanistan